Skip to main content

Table 2 Characteristics of the 66 infectious episodes that led to linezolid prescription in the study NICU (2010–2019)

From: Increasing use of linezolid in a tertiary NICU during a 10-year period: reasons and concerns for the future

  n (%)
Age at first symptoms (days)a 20 (9;33)
Hemodynamic instability 28 (42%)
Strains
Staphylococcus epidermidis 23 (35%)
Staphylococcus capitis 11 (17%)
Staphylococcus aureus 9 (14%)
Staphylococcus haemolyticus 3 (5%)
Enterobacter cloacae 1 (2%)
Staphylococcus gallinarum 1 (2%)
 No identification (clinical sepsis) 7 (11%)
 Polymicrobial 11 (17%)
Resistance to vancomycin 2 (3%)
Site of infection
 All bacteremia 39 (59%)
 Including persistent bacteremia 25 (64%)
 Isolated bacteremia 32 (48%)
 Pneumoniae 23 (35%)
 Other (CSF, peritoneal fluid) 4 (6%)
 No identification (clinical sepsis) 7 (11%)
First-line treatment
 Vancomycin 51 (77%)
 Linezolid 12 (18%)
 Other 3 (5%)
Antibiotic association (≥ 2 antibiotics) 46 (70%)
 including amikacin 43 (93%)
Delay before linezolid use (days)a 3 (2;6)
Linezolid treatment duration (days)a 7 (3;10)
Central line removal 25 (38%)
 In case of persistent bacteremia 21 (88%)
  1. aMedian (interquartiles)